Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XCUR 17

Next Previous
Drug Profile

XCUR 17

Alternative Names: XCUR17

Latest Information Update: 16 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Exicure
  • Developer Dermelix Biotherapeutics; Exicure
  • Class Anti-inflammatories; Antifibrotics; Antipsoriatics; Antisense oligonucleotides; Nucleic acids; Skin disorder therapies
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Alopecia; Netherton Syndrome; Psoriasis

Most Recent Events

  • 14 Dec 2022 Exciure terminates collaboration agreement with AbbVie
  • 28 May 2021 No recent reports of development identified for phase-I development in Psoriasis in Germany (Topical, Gel)
  • 01 May 2021 Exicure has patent protection for XCUR 17 in USA and foreign countries
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top